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SESSION I: LUNG CANCER DIAGNOSIS AND STAGINGLung cancer screening trials: The United States and beyondFrancine L. Jacobson, MD, MPH,a and Michael T. Jaklitsch, MDbThe National Lung Screening Trial (NLST) has for the first
time established a lung cancer–specific mortality benefit
through screening using low-dose computed tomography
(LDCT) of the chest. The 20% decrease in lung cancer–spe-
cific mortality and 7% decrease in all-cause mortality found
in the NLST begin a new chapter in the history of lung
cancer.1 The success of surgical treatment for early-stage
disease and the increasing number of targeted therapies
will continue to change the prognosis of lung cancer in con-
sort with early identification of the disease through screen-
ing, whether or not LDCT remains the initial screening test.
The decrease in lung cancer deaths due to LDCT is neces-
sary but not sufficient to establish computed tomography
(CT) screening guidelines and associated clinical care. Sec-
ondary findings from the NLSTwill provide data regarding
cost-effectiveness. Smaller trials in Europe are addressing
important issues, including the organization and frequency
of lung nodule follow-up. Although the demographics of
lung cancer vary in different countries and trials vary some-
what in eligibility, data pooling for meta-analyses may pro-
vide additional power and insight.THE MAGNITUDE OF THE PROBLEM
The United Nations Food and Agriculture Organization
estimated 1.3 billion cigarette smokers in the world in
2010.2 In developed countries where smoking has declined,
former smokers remain at high risk for lung cancer. Lung
cancer kills more than 1.3 million people annually. The
high mortality reflects the late presentation of disease
with metastases at time of diagnosis. Overall 5-year survival
is 10% to 20%, even in the United States, despite more than
70% 5-year survival of stage 1a disease.3
The growing cohort of lung cancer survivors is now
400,000. Empowering these survivors, who include individ-
uals, particularly women, who have never smoked, promises
to bring lung cancer into the open and lead screening for
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The Journal of Thoracic and Cfor breast cancer. The health care system does not yet
have the systems in place to provide lung cancer screening
CT in the same manner as mammography despite the fact
that lung cancer causes more deaths in women. Lessons
from mammography, historical lung cancer screening stud-
ies, and ongoing research in Europe contribute to our under-
standing and will influence the progression of lung cancer
screening from clinical trials into routine clinical practice.REQUIREMENTS FOR SCREENING
For screening to be viable, 5 conditions must be met: (1)
The disease must be common, (2) there must be effective
treatment for the disease, (3) a sensitive test must be avail-
able, (4) earlier treatment must decrease disease-specific
mortality, and (5) the test must be inexpensive and easily
performed. Although CT scanning is inexpensive compared
with medical care for more advanced lung cancer that is
generally identified by symptoms, it is an order of magni-
tude more costly than most screening tests that are univer-
sally recommended. This requires selection of patients
who have a particularly high risk of lung cancer through to-
bacco use and, to a lesser extent, environmental exposures
and genetic predispositions. Patients who have had lung
cancer and those who have a history of both smoking and
asbestos exposure often receive surveillance CT scans.
The use of clinical CT protocols, with radiation dose 3 to
5 or more times higher than LDCT protocols, should be
reassessed in these patients who could have equal benefit
with significantly lower radiation exposure. It is difficult
to conceive of the expansion of lung cancer screening to
those at low to moderate risk for lung cancer while CT scan-
ning is the primary screening procedure. An inexpensive
biomarker-based test that could be applied to blood or urine
would be ideal for the more complete population screening
that would be required to provide early identification of
lung cancer in the increasing number of lifetime non-
smokers who develop lung cancer.PREVIOUS LUNG CANCER SCREENING STUDIES
Many lessons have been learned from lung cancer screen-
ing trials during the past 50 years. The Mayo Clinic chest
x-ray (CXR) screening trial undertaken in the 1970s found
no mortality benefit after accounting for the cause of death
of every participant. This experience has informed study
design decisions made in various LDCT screening trials,
including the Early Lung Cancer Action Project (ELCAP)
and the NLST. In 1999, the ELCAP reported the screening
results for 1000 symptom-free volunteers who were at least
60 years of age with a smoking history of at least 10ardiovascular Surgery c Volume 144, Number 3 S3
TABLE 1. Lung cancer identified in the National Lung Screening
Trial by stage
Stage
649 positive by
CT screen
279 positive by
CXR screen
IA 129/635 (51.8%) 90/275 (32.7%)
IB 71/635 (11.2) 41/275 (14.9)
IIA 26/635 (4.1) 14/275 (5.1)
IIB 20/635 (3.1) 11/275 (4.0)
IIIA 59/635 (9.3) 35/275 (12.7)
IIIB 49/635 (7.7) 27/275 (9.8)
IV 81/635 (12.8) 57/275 (20.7)
CT, Computed tomography; CXR, chest x-ray.
TABLE 2. Lung cancer histology in the National Lung Screening Trial
Histology
649 positive by
CT screen
279 positive by
CXR screen
BAC (AIS) 95/646 (14.7%) 13/276 (4.7%)
Adenoca 258/646 (39.9) 112/276 (40.6)
Squamous 136/646 (21.1) 70/276 (25.4)
Large cell 28/646 (4.3) 12/276 (4.3)
NSCLC 75/646 (11.6) 40/276 (14.5)
Small cell 49/646 (7.6) 28/276 (10.1)
Carcinoid 5/646 (0.8) 1/276 (0.4)
CT, Computed tomography; CXR, chest x-ray; BAC, bronchioloalveolar carcinoma;
AIS, adenocarcinoma in situ; NSCLC, non–small cell lung cancer.
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noma skin cancer. The ELCAP design was a single-arm
study in which participants received both CXR and
LDCT. Additional sites were added around the world creat-
ing the International ELCAP. From 1993 to 2005, 31,657 in-
dividuals at high risk for lung cancer were screened using
LDCT for baseline and annual screening CT scans. The me-
dian age was 61 years with a median smoking history of 30
pack-years. Of the 484 lung cancers detected, 85% were
stage I, and the 10-year survival of these patients was
88%. Furthermore, 8 patients with stage I lung cancer iden-
tified in this trial who refused surgical therapy all died
within 5 years.4 The NLSTwas started by the National Can-
cer Institute in 2002 as a randomized trial to compare 3 an-
nual screenings by LDCT or CXR. There were 3 entry
criteria: age 55 to 74 years, 30 pack-year smoking history,
and smoking within the past 15 years. This trial (see below)
was stopped early with a 20% reduction in lung cancer–
specific mortality.1 For the first time, there was level 1 evi-
dence that LDCT screening reduced lung cancer deaths.
It is difficult to prevent trial arms from becoming more
similar, especially if 1 arm is told to obtain routine care.
The assignment of a specific routine level of care, such as
used in the NLST with an annual CXR, resulted in signifi-
cantly less crossover by participants seeking CT scans out-
side of the trial. ELCAP participants received both CT and
CXR. This provided a valuable understanding of the poten-
tial for CT to identify early-stage lung cancer, although the
single-arm study design precluded determination of mortal-
ity benefit. The experiences of ELCAP and contemporary
Japanese investigators opened the pathway to the identifica-
tion of early-stage lung cancers on CT scans.5-9
Along with the emergence of genetic mutation testing
and targeted therapies, this has in turn supported the impor-
tant reframing of the pathologic diagnosis of adenocarci-
noma, now based on biomarkers rather than histologic
pattern with lepidic growth.
RANDOMIZED CLINICAL TRIALS
The NLST randomized 53,454 individuals into 2 arms for
3 annual rounds of CT screening. Half of the participants re-
ceived LDCT, and half of the participants received CXR.
Screening was considered positive if the nodule was
4 mm or greater or suspicious lymphadenopathy or pleural
effusion was present. Nodules that were stable for 2 years
were reclassified as negative. In the LDCT group, 39.1%
had at least 1 positive screen; in the CXR group, 16%
had at least 1 positive screen. Some 24.2% of screens
were positive, of which 96.4% in the LDCT group and
94.5% in the CXR group were false-positives. All were fol-
lowed for at least 5 years after the last round of screening. In
the LDCT group, 1060 lung cancers were identified (645/
100,000 person-years); in the CXR group, 941 lung cancers
were identified (572/100,000 person-years). Of the 1060S4 The Journal of Thoracic and Cardiovascular Surgelung cancers in the LDCT group, 649 were discovered by
a positive screen; 44 lung cancers were screen negative,
and 367 additional lung cancers were diagnosed between
and after screens. Likewise, in the CXR group, 279 cancers
were discovered by a positive screen; 137 were screen neg-
ative, and 525 additional lung cancers were diagnosed be-
tween and after screens. The LDCT group had 10% less
mortality, although the LDCT and CXR groups were com-
parable in regard to demographics and aggressive tumors
unlikely to benefit from screening. The ability of CT scan-
ning to identify nonsolid lesions and enlarged lymph nodes
accounted for significant differences between the groups.
The ability to decrease lung cancer deaths through early
identification of disease is necessary but not sufficient for
creating guidelines for lung cancer screening. In the CXR
group, 30% of participants who presented later-stage lung
cancer (stage III and IV) had positive CXR screening test
results, whereas in the CT group, 43% of participants
who presented with stage III and IV lung cancer had posi-
tive CT screening test results. Distribution of stage and his-
tology is presented by group in Tables 1 and 2. This trial
came to the simple but powerful conclusion that screening
with LDCT reduces mortality from lung cancer.1EUROPEAN RANDOMIZED TRIALS
The Dutch-Belgian Nederlands-Leuvens Longkanker
Screening Onderzoek trial began the year after the NLST,
in 2003, and is continuing to 2014. It is the largest Europeanry c September 2012
TABLE 3. Comparison of randomized computed tomography trials
Trial
Screening,
Rounds Age (y)
Pack-y
history Quit (y)
NLST LDCT vs
CXR 3 3
55-74 30 <15
NELSON LDCT vs
usual 3 3
50-75 15-18.75 <10
DLCST LDCT vs
usual 3 5
50-70 20 <10 after
age 50 y
DANTE LDCT vs
usual 3 5
All baseline
CXR
60-74 men only 20 <10
ITALUNG LDCT vs
usual 3 4
55-69 20 <10
MILD LDCT vs
usual
Annual vs
biannual
50-75 <10
LUSI LDCT vs
usual 3 5
50-69 Heavy No
UKLS LDCT vs
usual (1)
50-75 5% risk in 5 y Multivariable
NLST, National Lung Screening Trial; LDCT, low-dose computed tomography; CXR,
chest x-ray; NELSON, Dutch-Belgian Nederlands-Leuvens Longkanker Screening
Onderzoek; DLCST, Danish Lung Cancer Screening Trial; DANTE, Detection and
Screening of Early Lung Cancer by Novel Imaging Technology andMolecular Essays
Trial; ITALUNG, CT RCT Tuscany;MILD,Multicentric Italian Lung Detection Trial
(Milan); LUSI, German component of the European trial on the Efficacy of
Multislice-CT Scan for the Early Detection of Lung Cancer; UKLS, UK Lung
Screening Trial.
Jacobson and Jaklitsch Session I: Lung Cancer Diagnosis and Stagingtrial to date with 16,000 participants, although it is less than
one third the size of NLST. This trial is randomizing partic-
ipants to LDCTat baseline, 1 year, and 3 years to no screen-
ing. Subjects gain entry through a population-based
enrollment. Questionnaires are used to judge the level of
risk of developing lung cancer without absolute rules re-
garding smoking history. This allows a heterogeneous study
group including nonsmokers with occupational exposures
and a strong family history of lung cancer.10
Numerous smaller randomized trials are being conducted
in Europe, including studies in Italy, France, and Denmark.
The Danish Lung Cancer Screening Trial has randomized
4104 subjects to LDCT for 5 years or no screening. Entry
criteria included 20 pack-year smoking history, forced expi-
ratory volume in 1 second of 30% or more, and ages be-
tween 50 and 70 years. Although the current small size of
the trial is limiting its current power, it has been designed
in accordance with the Dutch-Belgian randomized lung
cancer screening trial, the Nederlands-Leuvens Longkanker
Screening Onderzoek, to allow pooling of the data from
20,000 individuals, providing 80% power to detect
a 25% mortality reduction. Attention to nodule features,
smoking cessation, and pulmonary nodule management
are among the more specialized contributions being offered
by the smaller trials. Differences in tobacco use patterns andThe Journal of Thoracic and Cother factors that vary from country to country also may
provide insight. Meta-analyses will undoubtedly be per-
formed, although screening guidelines may need to vary
among countries because of such differences. A trial com-
parison is presented in Table 3.4,10-14
TRANSITION FROM CLINICALTRIAL TO
CLINICAL PRACTICE
Low-dose CT screening trials have varied in subtle ways,
such as (1) different entry criteria, (2) different nodule mea-
surement strategies, and (3) different follow-up algorithms.
The description of enrolled patients in the various trials will
be more important in the meta-analysis of data than the en-
try criteria. CT scans in these clinical trials have been read
primarily by subspecialty-trained thoracic radiologists
working in academic centers. In some trials, dual reading
and software tools for identification and measurement of
lung nodules exceed the realistic resources that are avail-
able in community settings.
The International Association for the Study of Lung Can-
cer consensus statement recommending screening for indi-
viduals with the same characteristics as NLST participants
provides the first basis for the logical extension of screening
beyond the clinical trial, moving into clinical practice.1,10
At the current time, the decision to seek low-dose CT
screening for lung cancer is an individual decision for
which the patient and the physician and radiologist must
share responsibility. Risk assessment is an integral part of
this process. CT scanners and scanning protocols should
follow the pattern established by the screening trials. This
will result in low-dose radiation with high-quality images.
Population guidelines may need to be tailored to popula-
tions in different countries because of differences in smok-
ing behavior and other risk factors for lung cancer, as well
as financial constraints in the delivery of health care.
QUESTIONS TO BE ANSWERED
The Pisa Position Statement on March 4, 2011, listed 8
questions that need to be answered: (1) What is the optimal
target population and how could individual risk be assessed
to select a population at higher risk? (2) Could early detec-
tion biomarkers play a role in risk assessment? (3) What is
the optimal management of suspicious nodules detected on
CT? (4) What is the optimal screening protocol (age range,
screen interval, number of screening rounds, value of recall
CT scans)? (5) What is the effect of overdiagnosis? (6)
What is the cost-effectiveness of CT screening? (7) What
will CT screening add to an antismoking policy? (8) Is
the efficacy of CT screening different in current versus for-
mer smokers?15
CONCLUSIONS
The largest randomized prospective trial using LDCT to
screen for lung cancer, the NLST, has provided level 1ardiovascular Surgery c Volume 144, Number 3 S5
Session I: Lung Cancer Diagnosis and Staging Jacobson and Jaklitschevidence that screening reduces lung cancer mortality in 30
pack-year smokers between the ages of 55 and 74 years.
LDCT screening for lung cancer will allow more patients
to benefit from the highly successful treatments now avail-
able to treat most early-stage lung cancers. The interdisci-
plinary development and continuing evaluation of
guidelines for screening, surveillance, and systematic nod-
ule management will usher in a new era in the treatment of
lung cancer.
References
1. The National Lung Screening Trial Research Team. Reduced lung-cancer mor-
tality with low-dose computed tomographic screening. N Engl J Med. 2011;
365:395-409.
2. Food and Agriculture Organization of the United Nations. Higher world tobacco
use expected by 2010—growth rate slowing down; January 8, 2004. Available
at: http://www.fao.org/english/newsroom/news/2003/26919-en.html. Accessed
May 28, 2012.
3. Howlader N, Noone AM, KrapchoM, Neyman N, Aminou R, Altekruse SF, et al,
eds. SEER Cancer Statistics Review, 1975-2009 (Vintage 2009 Populations). Be-
thesda, MD: National Cancer Institute. Available at: http://seer.cancer.gov/csr/
1975_2009_pops09/. Accessed May 28, 2012.
4. The International Early Lung Cancer Action Program Investigators. Survival of
patients with Stage I lung cancer detected on CT screening. N Engl J Med. 2006;
355:1763-71.
5. Kaneko M, Eguchi K, Ohmatsu H, Kakinuma R, Nanuke T, Suemasu K, et al.
Peripheral lung cancer: screening and detection with low-dose spiral CT versus
radiography. Radiology. 1996;201:798-802.S6 The Journal of Thoracic and Cardiovascular Surge6. Sone S, Takashima S, Li F, Yang Z, Honda T, Maruyama Y, et al. Mass screening
for lung cancer with mobile spiral computed tomography scanner. Lancet. 1998;
351:1242-5.
7. Henschke CI, McCauley DI, Yankelevitz DF, Naidich DP, McGuinness G,
Miettinen OS, et al. Early lung cancer action project: overall design and findings
from baseline screening. Lancet. 1999;354:99-105.
8. Marcus PM, Bergstralh EJ, Fagerstrom RM, Williams DE, Fontana R,
Taylor WF, et al. Lung cancer mortality in the Mayo Lung Project: impact of ex-
tended follow-up. J Natl Cancer Inst. 2000;92:1308-16.
9. Swensen SJ, Jett JR, Harman TE, Midthun DE, Mandrekar SJ, Hillman SL, et al.
CT screening for lung cancer: five-year prospective experience. Radiology. 2005;
235:259-65.
10. van Iersel CA, deKoningHJ, DraismaG,MaliWPTM, Scholten ET,NackaertsK,
et al. Risk-based selection from the general population in a screening trial: selec-
tion criteria, recruitment and power for the Dutch-Belgian randomized lung can-
cer multi-slice CT screening trial (NELSON). Int J Cancer. 2006;120:868-74.
11. Infante M, Lutman FR, Cavuto S, Brambilla G, Chiesa G, Passera E, et al. Lung
cancer with spiral CT. Baseline results of the randomized DANTE trial. Lung
Cancer. 2008;59:355-63.
12. Pedersen JH, Ashraf H, Dirksen A, Bach K, Hansen H, Toennesen P, et al. The
Danish randomized lung cancer CT screening trial–overall design and results
of the prevalence round. J Thorac Oncol. 2009;4:608-14.
13. Nair A, Hansell DM. European and North American lung cancer screening expe-
rience and implications for pulmonary nodule management. Eur Radiol. 2011;
21:2445-54.
14. Field JK, Smith RA, Aberle DR, Oudkerk M, Baldwin DR, Yankelevitz D, et al.
International Association for the Study of Lung Cancer Computed Tomography
Screening Workshop 2011 report. J Thorac Oncol. 2012;7:10-9.
15. International workshop on randomized lung cancer screening trials. State of the
art in Europe after early conclusion of the US National Lung Screening Trial. The
Pisa Position Statement. Pisa, Italy; March 4, 2011.ry c September 2012
